Tianyin CFO/CBDO Dr. James J. Tong Invited to Attend Cold Spring Harbor Asia Conference Opening Ceremony and James Watson Cancer Symposium at Suzhou, China
SUZHOU, China, April 4 /PRNewswire-Asia/ — Cold Spring Harbor Asia (CSHA) is the Asia hub of Cold Spring Harbor Laboratory (CSHL), which is headed by the DNA structure discover, Dr. James D. Watson and President and CEO of CSHL, Dr. Bruce Stillman, who spearhead the effort in molecular medicine and genetics for better diagnostics and treatments for neurological diseases, cancer and other major causes of human suffering. Home to seven Nobel laureates, CSHL has played a pivotal role in the emergence of molecular genetics, the scientific foundation for the contemporary revolution in biotechnology. CSHA’s honorary scientific advisory board consists of leaders of science and health care industry in both the US and China, such as Dr. James D. Watson, CSHL, USA, Zhu Chen, Minister of Health, PRC and Zhou Guang Zhao, Chinese Association for Science & Technology, PRC.
“Tianyin achieved 10 new product approvals by the State Food and Drug Administration (SFDA) in 2009. With a series of pipeline candidates filed and pending for approval targeting various indications this year, we further strengthen our effort in seeking potential opportunities to bridge scientific fundamentals with clinical application, and to extract the industrial value from basic biotech research,” said Dr. Tong. “The CSHA operation was completed expeditiously within two years under the leadership of Dr. Maoyen Chi, CEO of CSHA, which coincided with a profound transition in China health care industry, and mirrored the vision and commitment from both US and China scientific communities.”
The CSHA conference (http://meetings.cshl.edu/CSHAsia/index.html) is to be held from April 6-11 of 2010, in Suzhou, China.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine (“TCM”) in China. It was established in 1994 and acquired by the current management team in August 2003. Its comprehensive product portfolio consists of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and a R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.
For more information, please contact: James Jiayuan Tong M.D. Ph.D. Chief Financial Officer, Chief Business & Development Officer Director Tianyin Pharmaceutical Co., Inc. www.tianyinpharma.com Dr.Tong.TPI@gmail.com Dr.Tong@tianyinpharma.com
SOURCE Tianyin Pharmaceutical Co., Inc.